Blackstone Life Sciences will invest up to $1.5 billion to fund Pfizer’s obesity program centered on berobenatide, a potentially once-monthly GLP-1 candidate the company gained through its $10 billion acquisition of Metsera. The co-funding is intended to bankroll multiple late-stage trials as Pfizer pushes toward an obesity launch.